Increased mortality in patients with hematologic malignancies treated with proton pump inhibitors: a nationwide cohort study

References

• Savarino V, Dulbecco P, de Bortoli N, et al. The appropriate use of proton pump inhibitors (PPIs): need for a reappraisal. Eur J Intern Med. 2017;37:19–24.
   PubMed Web of Science ®Google Scholar
• Sartori S, Trevisani L, Nielsen I, et al. Randomized trial of omeprazole or ranitidine versus placebo in the prevention of chemotherapy-induced gastroduodenal injury. J Clin Oncol. 2000;18(3):463–467.
   PubMed Web of Science ®Google Scholar
• Olbe L, Carlsson E, Lindberg P. A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole. Nat Rev Drug Discov. 2003;2(2):132–139.
   PubMed Web of Science ®Google Scholar
• Shin JM, Sachs G. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep. 2008;10(6):528–534.
   PubMedGoogle Scholar
• Liu W, Baker SS, Trinidad J, et al. Inhibition of lysosomal enzyme activities by proton pump inhibitors. J Gastroenterol. 2013;48(12):1343–1352.
   PubMed Web of Science ®Google Scholar
• Mullin JM, Gabello M, Murray LJ, et al. Proton pump inhibitors: actions and reactions. Drug Discov Today. 2009;14(13–14):647–660.
   PubMed Web of Science ®Google Scholar
• Xie Y, Bowe B, Li T, et al. Risk of death among users of proton pump inhibitors: a longitudinal observational cohort study of United States veterans. BMJ Open. 2017;7(6):e015735.
   PubMed Web of Science ®Google Scholar
• Cheema E. Investigating the association of proton pump inhibitors with chronic kidney disease and its impact on clinical practice and future research: a review. J Pharm Policy Pract. 2019;12:6.
   PubMedGoogle Scholar
• Llorente C, Jepsen P, Inamine T, et al. Gastric acid suppression promotes alcoholic liver disease by inducing overgrowth of intestinal enterococcus. Nat Commun. 2017;8(1):837.
   PubMedGoogle Scholar
• Dial S, Delaney JA, Barkun AN, et al. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA. 2005;294(23):2989–2995.
   PubMed Web of Science ®Google Scholar
• Laheij RJ, Sturkenboom MC, Hassing RJ, et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA. 2004;292(16):1955–1960.
   PubMed Web of Science ®Google Scholar
• Gulmez SE, Holm A, Frederiksen H, et al. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med. 2007;167(9):950–955.
   PubMedGoogle Scholar
• Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004;4(11):891–899.
   PubMed Web of Science ®Google Scholar
• Cardone RA, Casavola V, Reshkin SJ. The role of disturbed pH dynamics and the na+/H + exchanger in metastasis. Nat Rev Cancer. 2005;5(10):786–795.
   PubMed Web of Science ®Google Scholar
• Harguindey S, Arranz JL, Wahl ML, et al. Proton transport inhibitors as potentially selective anticancer drugs. Anticancer Res. 2009;29(6):2127–2136.
   PubMed Web of Science ®Google Scholar
• Fais S, Venturi G, Gatenby B. Microenvironmental acidosis in carcinogenesis and metastases: new strategies in prevention and therapy. Cancer Metastasis Rev. 2014;33(4):1095–1108.
   PubMed Web of Science ®Google Scholar
• Wang BY, Zhang J, Wang JL, et al. Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer. J Exp Clin Cancer Res. 2015;34(1):85.
   PubMedGoogle Scholar
• Calcinotto A, Filipazzi P, Grioni M, et al. Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes. Cancer Res. 2012;72(11):2746–2756.
   PubMed Web of Science ®Google Scholar
• Scaringi L, Cornacchione P, Ayroldi E, et al. Omeprazole induces apoptosis in Jurkat cells. Int J Immunopathol Pharmacol. 2004;17(3):331–342.
   PubMed Web of Science ®Google Scholar
• Luciani F, Spada M, De Milito A, et al. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Cancer Inst. 2004;96(22):1702–1713.
   PubMed Web of Science ®Google Scholar
• Yeo M, Kim DK, Kim YB, et al. Selective induction of apoptosis with proton pump inhibitor in gastric cancer cells. Clin Cancer Res. 2004;10(24):8687–8696.
   PubMed Web of Science ®Google Scholar
• De Milito A, Iessi E, Logozzi M, et al. Proton pump inhibitors induce apoptosis of human B-cell tumors through a caspase-independent mechanism involving reactive oxygen species. Cancer Res. 2007;67(11):5408–5417.
   PubMed Web of Science ®Google Scholar
• Azzarito T, Venturi G, Cesolini A, et al. Lansoprazole induces sensitivity to suboptimal doses of paclitaxel in human melanoma. Cancer Lett. 2015;356(2 Pt B):697–703.
   PubMed Web of Science ®Google Scholar
• Zeng X, Liu L, Zheng M, et al. Pantoprazole, an FDA-approved proton-pump inhibitor, suppresses colorectal cancer growth by targeting T-cell-originated protein kinase. Oncotarget. 2016;7(16):22460–22473.
   PubMedGoogle Scholar
• Tvingsholm SA, Dehlendorff C, Osterlind K, et al. Proton pump inhibitor use and cancer mortality. Int J Cancer. 2018;143(6):1315–1326.
   PubMed Web of Science ®Google Scholar
• Hill HC, Conway TF, Jr., Sabel MS, et al. Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease. Cancer Res. 2002;62(24):7254–7263.
   PubMed Web of Science ®Google Scholar
• Papagerakis S, Bellile E, Peterson LA, et al. Proton pump inhibitors and histamine 2 blockers are associated with improved overall survival in patients with head and neck squamous carcinoma. Cancer Prev Res (Phila). 2014;7(12):1258–1269.
   PubMed Web of Science ®Google Scholar
• Brown JP, Tazare JR, Williamson E, et al. Proton pump inhibitors and risk of all-cause and cause-specific mortality: a cohort study. Br J Clin Pharmacol. 2021;87(8):3150–3161.
   PubMed Web of Science ®Google Scholar
• Indini A, Petrelli F, Tomasello G, et al. Impact of use of gastric-acid suppressants and oral anti-cancer agents on survival outcomes: a systematic review and meta-analysis. Cancers (Basel). 2020;12(4):998.
   PubMed Web of Science ®Google Scholar
• Thygesen LC, Ersboll AK. When the entire population is the sample: strengths and limitations in register-based epidemiology. Eur J Epidemiol. 2014;29(8):551–558.
   PubMed Web of Science ®Google Scholar
• Pedersen CB. The danish civil registration system. Scand J Public Health. 2011;39(7):22–25.
   PubMed Web of Science ®Google Scholar
• Schmidt M, Schmidt SA, Sandegaard JL, et al. The danish national patient registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449–490.
   PubMed Web of Science ®Google Scholar
• Sundhedsdatastyrelsen. Medstat.dk: the Danish health data authority (Sundhedsdatastyrelsen). 2016. Available from http://www.medstat.dk/en
   Google Scholar
• Helweg-Larsen K. The danish register of causes of death. Scand J Public Health. 2011;39(7):26–29.
   PubMed Web of Science ®Google Scholar
• Herranz P. M. Is there an overprescription of proton pump inhibitors in oncohematologic patients undergoing ambulatory oncospecific treatment? Farm Hosp. 2016;40(5):436–446.
   PubMedGoogle Scholar
• Moayyedi P, Eikelboom JW, Bosch J, et al. Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin. Gastroenterology. 2019;157(3):682–691 e2.
   PubMed Web of Science ®Google Scholar